Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice

Gut

Volumn 63, Issue 1, 2014, Pages 170-178

  Lu, Yan ^a   Ma, Zhimin ^a   Zhang, Zhijian ^a   Xiong, Xuelian ^a   Wang, Xiaolin ^a   Zhang, Huijie ^a   Shi, Guojun ^a   Xia, Xuefeng ^b   Ning, Guang ^a,c   Li, Xiaoying ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c University of Shanghai   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FARNESOID X RECEPTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR YY1; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FXR GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INTRON; LIVER METABOLISM; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

NONALCOHOLIC STEATOHEPATITIS; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; FATTY LIVER; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIGLYCERIDES; UP-REGULATION; YY1 TRANSCRIPTION FACTOR;

EID: 84889632658     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303150     Document Type: Article

References (43)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
2. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-23.
3. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5. (Pubitemid 29528333)
4. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:99-112.
6. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
7. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23. (Pubitemid 36397405)
8. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004;8:501-19. (Pubitemid 39141139)
9. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008;294:1281-7.
10. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009;106:15430-5.
11. Kammoun HL, Chabanon H, Hainault I, et al. GRP78 expression inhibits insulin and ER stress induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009;119:1201-15.
12. Mitsuyoshi H, Yasui K, Harano Y, et al. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res 2009;39:366-73.
13. Thomas MJ, Seto E. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 1999;236:197-208. (Pubitemid 29375109)
14. Donohoe ME, Zhang X, McGinnis L, et al. Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality.Mol Cell Biol 1999;19:7237-44. (Pubitemid 29441903)
15. Gordon S, Akopyan G, Garban H, et al. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006;25:1125-42.
16. Huang HY, Li X, Liu M, et al. Transcription factor YY1 promotes adipogenesis via inhibiting CHOP-10 expression. Biochem Biophys Res Commun 2008;375:496-500.
17. Blättler SM, Cunningham JT, Verdeguer F, et al. Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab 2012;15:505-17.
18. Logsdon BA, Hoffman GE, Mezey JG. Mouse obesity network reconstruction with a variational Bayes algorithm to employ aggressive false positive control. BMC Bioinformatics 2012;2:13:53.
19. Ma X, Xu L, Wang S, et al. Deletion of steroid coactivator-3 ameliorates hepatic steatosis. J Hepatol 2011;55:445-52.
20. Espenshade PJ. SREBPs: sterol-regulated transcription factors. J Cell Sci 2006;119:973-6.
21. Chen G, Liang G, Ou J, et al. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 2004;101:11245-50. (Pubitemid 39038332)
22. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-18. (Pubitemid 39071696)
23. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517-26.
24. Wang HT, Garzon R, Sun H, et al. NF-κB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008;14:369-81.
25. Wang HT, Hertlein E, Bakkar N, et al. NF-κB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007;27:4374-87. (Pubitemid 46906562)
26. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7. (Pubitemid 46024993)
27. Könner AC, Brüning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab 2011;22:16-23.
28. Klöting N, Follak N, Klöting I. Diabetes per se and metabolic state influence gene expression in tissue-dependent manner of BB/OK rats. Diabetes Metab Res Rev 2005;21:281-7. (Pubitemid 40716161)
29. Zabel MD, Wheeler W, Weis JJ, et al. Yin Yang 1, Oct1 and NFAT-4 form repeating, cyclosporin-sensitive regulatory modules within the murine CD21 intronic control region. J Immunol 2002;168:3341-50. (Pubitemid 34250397)
30. Foti DM, Reichardt JK. YY1 binding within the human HSD3B2 gene intron 1 is required for maximal basal promoter activity: identification of YY1 as the 3beta1-A factor. J Mol Endocrinol 2004;33:99-119. (Pubitemid 39206351)
31. He CQ, Ding NZ, Fan W. YY1 repressing peroxisome proliferator activated receptor delta promoter. Mol Cell Biochem 2008;308:247-52.
32. Deng Z, Wan M, Cao P, et al. Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene 2009;28:3746-57.
33. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5. (Pubitemid 29289663)
34. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006-11. (Pubitemid 43212212)
35. Zhang Y, Castellani LW, Sinal CJ, et al. Peroxisome proliferator- activated receptor-γ coactivator 1α regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004;18:157-69. (Pubitemid 38141784)
36. Kemper JK, Xiao Z, Ponugoti B, et al. FXR acetylation is normally dynamically regulated by p300 and Sirt1 but constitutively elevated in metabolic disease states. Cell Metab 2009;10:392-404.
37. Haeusler RA, Pratt-Hyatt M, Welch CL, et al. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab 2012;15:65-74.
38. Lee J, Seok S, Yu P, et al. Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice. Hepatology 2012;56:108-17.
39. Sandoval DD, Mautino G, Martin G, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004;53:890-8. (Pubitemid 38436600)
40. Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int 2010;4:741-8.
41. Fiorucci S, Rizzo G, Donini A, et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007;13:298-309. (Pubitemid 47017005)
42. Moore DD. Nuclear receptors reverse McGarry's vicious cycle to insulin resistance. Cell Metab 2012;15:615-22.
43. Fuchs M. Non-alcoholic fatty liver disease: the bile cid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012;2012:934396.